SecBot SecBot
8-K ·Filed Aug 10, 2026

TCMD

TACTILE SYSTEMS TECHNOLOGY INC
BULLISH
Impact 6/10
Horizonimmediate Processed3mo ago SEC0001104659-26-093346
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong Q2 beat and raised profitability trajectory (net income +142% YoY) support a bullish read-through for near-term price action, despite the slight guidance trim attributed to temporary DME destocking. Watch for the Q3 2026 earnings call for updates on AffloVest ordering normalization and any further guidance adjustments, which could clarify the recovery trajectory for the airway clearance segment.

DirectionBullish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$24.15
T+0 close · Aug 10, 2026 · via day close
Latest settled
+12.55%
T+60 · $27.18
Vs SPY
+13.03%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $24.15entry
  2. T+1 · 3mo ago +1.49%α +1.24% · $24.51
  3. T+5 · 3mo ago −1.24%α −0.84% · $23.85
  4. T+20 · 2mo ago −8.82%α −7.76% · $22.02
  5. T+60 · 13d ago +12.55%α +13.03% · $27.18
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Tactile Systems Technology reported Q2 2026 results with total revenue of $85.7 million (up 9% YoY), net income of $7.8 million ($0.34 per diluted share) versus $3.2 million in Q2 2025, and adjusted EBITDA of $11.4 million. Revenue slightly beat the $85.5M consensus estimate, while EPS of $0.34 far exceeded the $0.14 consensus forecast. However, the company narrowed its full-year 2026 revenue guidance to $360M–$366M (from $360M–$368M) due to temporary inventory destocking at DME providers, partially offsetting the strong quarter.

Key Financial Metrics

EPS
$0.34
est $0.14 · +142.9%
Revenue
$85.7M
est $85.5M · +0.2% · +8.6% YoY
Rating
strong beat
Guidance
$360M-$366M
lowered
Gross Margin
76%

Key Facts

  • Total revenue of $85.7 million for Q2 2026, up 9% YoY from $78.9 million
  • Net income of $7.8 million ($0.34 diluted EPS) vs $3.2 million ($0.14) in Q2 2025
  • Gross margin expanded to 76% from 75% in Q2 2025
  • Adjusted EBITDA of $11.4 million, up 49% from $7.7 million
  • Lymphedema product revenue grew 12% to $73.6 million; airway clearance revenue fell 7% to $12.1 million due to DME inventory dynamics
  • FY 2026 revenue guidance narrowed to $360M–$366M (prior: $360M–$368M); reaffirmed adjusted EBITDA guidance of $49M–$51M
  • Repurchased $5.3 million of stock in Q2 2026; $18.7 million remaining under the $25M buyback program
  • Cash balance of $69.9 million with zero debt as of June 30, 2026

Financial Impact

Q2 revenue beat consensus by +0.2% ($85.7M vs $85.5M); EPS of $0.34 significantly exceeded consensus of $0.14 (143% beat). Full-year guidance midpoint lowered by $1M to $363M, representing ~10% YoY growth.

revenueepsgross marginadjusted EBITDAguidance

Risk Factors

  • Airway clearance revenue declined 7% YoY due to DME inventory destocking; continued weakness could pressure future revenue growth
  • Narrowed FY 2026 revenue guidance range signals less confidence in full-year top-line acceleration
  • Competitive dynamics in the airway clearance market could affect AffloVest adoption
  • Litigation and acquisition integration costs ($156K in Q2) weigh on reported net income

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-093346
Document: tcmd-20260810x8k.htm0001104659-26-093346
Document: 0001104659-26-093346-index-headers.html0001104659-26-093346
Document: 0001104659-26-093346-index.html0001104659-26-093346
Document: 0001104659-26-093346.txt0001104659-26-093346
8-K Data (Synthetic)0001104659-26-093346

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026